Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy

Next Previous
Trial Profile

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Defosbarasertib (Primary) ; Azacitidine; Azacitidine; Venetoclax
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 24 Mar 2022 According to ClinicalTrials.gov record, protocol has been amended as treatment arm changed from 8 to 13, time frame of primary endpoint changed from 28 days to 42 months, other endpoint also changed, Study phase changes from 1/2 to phase 1
  • 19 Jul 2021 Status changed from completed to discontinued.
  • 27 May 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top